The treatment of inflammatory bowel disease with 6‐mercaptopurine or azathioprine

Alimentary Pharmacology and Therapeutics - Tập 15 Số 11 - Trang 1699-1708 - 2001
Ole Haagen Nielsen1, Ben Vainer, J Rask-Madsen
1Department of Gastroenterology C, Herlev Hospital, University of Copenhagen, Denmark. [email protected]

Tóm tắt

The thioguanine derivative, azathioprine, is a prodrug of 6‐mercaptopurine that is further metabolized by various enzymes present in the liver and gut. Azathioprine and 6‐mercaptopurine have been used in the treatment of inflammatory bowel disease, i.e. ulcerative colitis and Crohn’s disease, for more than 30 years. However, widespread use of azathioprine or 6‐mercaptopurine in inflammatory bowel disease is of more recent origin, the primary reason being a long‐standing debate on the efficacy of these agents in inflammatory bowel disease. Both drugs are slow acting, which is why clinical efficacy cannot be expected until several weeks or even months of treatment have elapsed. Consequently, azathioprine and 6‐mercaptopurine have no place as monotherapy in the treatment of acute relapsing inflammatory bowel disease.Today, azathioprine and 6‐mercaptopurine are the most commonly used immunomodulatory drugs in the treatment of inflammatory bowel disease. Their clinical effects are probably identical, although their exact mode of action is still unknown. The mode of action of azathioprine is thought to be multifactorial, including conversion to 6‐mercaptopurine (which acts as a purine antimetabolite), possible blockade of thiol groups by alkylation, inhibition of several pathways in nucleic acid biosynthesis (preventing proliferation of cells involved in the determination and amplification of the immune response) and damage to DNA through the incorporation of thiopurine analogues. However, 6‐thioguanine nucleotides may accumulate in toxic doses in myeloid precursor cells, resulting in life‐threatening myelosuppression. Azathioprine and 6‐mercaptopurine are further known to alter lymphocyte function, reduce the number of lamina propria plasma cells and affect natural killer cell function.The purpose of this comprehensive review is to suggest guidelines for the application of azathioprine and 6‐mercaptopurine in the treatment of inflammatory bowel disease.

Từ khóa


Tài liệu tham khảo

10.1016/S0300-2977(96)00065-4

10.1097/00007691-199810000-00002

10.1016/0378-4347(87)80340-7

Sandborn WJ., 1996, A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6‐mercaptopurine, cyclosporine, and methotrexate, Am J Gastroenterol, 91, 423

10.1007/BF02220605

10.1016/0140-6736(90)91745-V

10.1046/j.1365-2125.1997.t01-1-00607.x

10.1146/annurev.pharmtox.39.1.19

10.1046/j.1365-2036.2000.00812.x

Woodson LC, 1983, Thiopurine methyltransferase: aromatic thiol substrates and inhibition by benzoic acid derivatives, Mol Pharmacol, 24, 471

10.1053/gast.2000.9120

10.7326/0003-4819-123-2-199507150-00009

10.1136/gut.48.5.642

10.1080/09629359891045

10.1016/S0016-5085(99)70445-2

10.1016/S0016-5085(98)84200-5

10.1097/00043426-199605000-00009

10.1111/j.1365-2125.1995.tb04478.x

10.1080/003655298750027290

Pearson DC, 2000, Azathioprine for maintaining remission of Crohn’s disease, Cochrane Database Syst Rev, 2, CD000067

10.1016/S0016-5085(00)85288-9

10.1016/0016-5085(93)90709-L

10.1136/gut.37.5.674

Sandborn W, 2000, Azathioprine or 6‐mercaptopurine for inducing remission of Crohn’s disease, Cochrane Database Syst Rev, 2, CD000545

10.1016/S0016-5085(97)70027-1

10.1016/S0140-6736(78)92524-2

10.1016/S0140-6736(96)90402-X

10.1016/S0016-5085(00)70007-2

10.1016/S0140-6736(99)00442-0

10.1056/NEJM198005013021801

10.1016/S0140-6736(71)90598-8

10.1016/0016-5085(95)90747-5

10.1007/BF01318372

10.1097/00004836-199707000-00007

10.1023/A:1005569808947

10.1046/j.1365-2036.2000.00872.x

10.1002/ibd.3780060314

10.1136/gut.37.5.674

10.1136/bmj.305.6844.20

George J, 1996, The long‐term outcome of ulcerative colitis treated with 6‐mercaptopurine, Am J Gastroenterol, 91, 1711

Korelitz BI., 2000, A history of immunosuppressive drugs in the treatment of inflammatory bowel disease: origins at the Mount Sinai Hospital, Mt Sinai J Med, 67, 214

10.1136/gut.34.8.1081

10.7326/0003-4819-111-8-641

10.2165/00002018-200023050-00006

10.1080/003655299750025633

10.1016/S0016-5085(98)70251-3

10.1007/s005350050281

Ponticelli C, 1999, Renal transplantation, past, present, future, J Nephrol, 12, S105

10.1016/0145-2126(93)90063-Q

10.1001/archderm.1995.01690140077013

Colonna K, 1994, The role of leukopenia in the 6‐mercaptopurine‐induced remission of refractory Crohn’s disease, Am J Gastroenterol, 89, 362

10.1016/S0016-5085(00)85293-2

10.1002/gepi.1370120102

Weinshilboum RM, 1980, Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity, Am J Hum Genet, 32, 651

10.1016/S0016-5085(00)70140-5

10.1016/S0016-5085(00)70354-4

10.1111/j.1365-2133.1997.tb08765.x

10.1097/00007890-199603150-00009

10.1136/gut.47.4.514

10.1016/S0140-6736(94)92150-4

10.1016/S0016-5085(00)83091-7

10.1016/S0016-5085(00)70353-2

Francella A, 1996, 6‐Mercaptopurine is safe therapy for child bearing patients with inflammatory bowel disease: a case‐controlled study, Gastroenterology, 110, A909

10.1016/S0889-857X(05)70320-3

Tennembaum R, 1999, Pregnancy outcome in inflammatory bowel disease, Gastroenterol Clin Biol, 23, 464

10.2165/00002018-199819050-00006

Alstead EM, 1989, Pregnancy in inflammatory bowel disease patients on azathioprine, Gut, 30, 718

Davidson JM, 1984, Pregnancy in women with renal allografts, Semin Nephrol, 4, 240

10.3109/00365528209181034

Committee on Drugs, American Academy of Pediatrics, 1994, The transfer of drugs and other chemicals into human milk, Pediatrics, 93, 137, 10.1542/peds.93.1.137

10.1111/j.1572-0241.2000.01846.x

10.1001/archinte.160.5.610

10.1016/0016-5085(90)91027-4

10.1016/0049-0172(88)90002-9

Thông tin
Thông tin xuất bản

Alimentary Pharmacology and Therapeutics

Tập 15 Số 11

1699-1708

Thông tin tác giả